ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Viral therapy"

  • 2018 American Transplant Congress

    Prospective, Multi-Center Observational Study of Cell-Mediated Immunity for Cytomegalovirus Infection in Kidney Transplant Recipients

    D. Kumar,1 P. Chin-Hong,2 L. Kayler,3 D. Wojciechowski,4 A. Limaye,5 O. Gaber,6 S. Ball,7 A. Mehta,8 T. Blanchard,9 C. Kotton.4

    1UHN, Toronto, Canada; 2UCSF, San Francisco; 3ECMC, Buffalo; 4MGH, Boston; 5UOWMC, Seattle; 6WCMC, Houston; 7UHB, Birmingham, United Kingdom; 8EmoryU, Atlanta; 9Oxford Diag, Marlborough.

    Background:T-cell-mediated immunity (CMI) is crucial for the control of CMV infection post-transplant. We evaluated a novel EliSpot assay to determine whether CMI results could predict…
  • 2018 American Transplant Congress

    Impact of Direct Acting Antivirals of Hepatitis C Virus Therapy on Tacrolimus Dosing Post-Liver Transplant

    A. Bixby, L. Fitzgerald, R. Leek, J. Mellinger, S. Tischer.

    Michigan Medicine, Ann Arbor, MI.

    Background: Direct acting antivirals (DAA) have transformed hepatitis C virus (HCV) management post-liver transplant (LT). As HCV clears, hepatic metabolism improves, resulting in decreased tacrolimus…
  • 2018 American Transplant Congress

    Direct-Acting Antiviral Therapy Immune-Mediated Graft Dysfunction in Liver Transplant Recipients with Hepatitis C

    C. Chan,1 E. Agudelo,2 J. Haydek,3 M. Hoteit,4 M. Laurito,5 J. Norvell,3 T. Schiano,6 N. Terrault,2 E. Verna,5 A. Yang,1 J. Levitsky.1

    1Northwestern University, Chicago, IL; 2UCSF, San Francisco, CA; 3Emory University, Atl, GA; 4University of Pennsylvania, Philadelphia, PA; 5Columbia University, NY, NY; 6Mount Sinai, NY, NY.

    Background and Aims:Interferon (IFN) treatment of hepatitis C virus (HCV) infection after liver transplantation (LT) can result in severe immune-mediated graft dysfunction (IGD). The occurrence…
  • 2018 American Transplant Congress

    Incidence of Acute Cellular Rejection in Liver Transplant Patients Receiving Direct Acting Antivirals for Hepatitis C Treatment

    D. Bley,1 L. Sagardia,1 R. Ford,2 S. Todd.1

    1Pharmacy, Emory University Hospital, Atlanta, GA; 2School of Medicine, Emory University, Atlanta, GA.

    Direct acting antivirals (DAAs) have been used for the treatment of hepatitis C (HCV) in liver transplant patients since early on after their approval, however…
  • 2018 American Transplant Congress

    An Individualized Strategy Using Virus and Immune-Based Markers to Prevent Cytomegalovirus Disease after Face Transplantation

    R. Razonable, H. Amer, S. Mardini.

    Mayo Clinic, Rochester, MN.

    Introduction: There is limited data on CMV prevention after face transplantation. We report an individualized approach using prophylaxis followed by surveillance and preemptive therapy guided…
  • 2017 American Transplant Congress

    Kidney Transplant Allocation with CMV Matching Reduces CMV Infection and Related Costs.

    J. Lockridge,1 E. Langewisch,2 D. Basuli,1 A. Olyaei,3 C. Shaut,4 D. Norman.1

    1Division of Nephrology, Department of Medicine, Oregon Health and Science University, Portland, OR; 2Nephrology, University of Nebraska, Omaha, NE; 3Pharmacy, Oregon Health and Sciences University, Portland, OR; 4Immunogenetics and Transplant, Oregon Health and Sciences University, Portland, OR

    Cytomegalovirus (CMV) infection is a major cause of morbidity, mortality, and shortened graft survival in kidney transplant recipients. Efforts to prevent CMV infection have traditionally…
  • 2017 American Transplant Congress

    Kidney Allocation Using CMV Matching Optimizes Low and High Risk Profiles for Prevention of CMV Infection in Kidney Transplant Recipients.

    J. Lockridge,1 E. Langewisch,2 D. Basuli,1 A. Olyaei,3 C. Shaut,4 D. Norman.1

    1Division of Nephrology, Department of Medicine, Oregon Health and Science University, Portland, OR; 2Nephrology, University of Nebraska, Omaha, NE; 3Pharmacy, Oregon Health and Sciences University, Portland, OR; 4Immunogenetics and Transplant, Oregon Health and Sciences University, Portland, OR

    Cytomegalovirus (CMV) confers a major impact on morbidity, mortality, and graft survival in kidney transplant recipients. Efforts to prevent CMV disease and infection have traditionally…
  • 2017 American Transplant Congress

    Impact of Everolimus Added to a De Novo Belatacept Regimen on the Risk of BK Viremia After Kidney Transplant.

    C. Larsen,1 M. Alseiari,2 S. Chandran,2 F. Vincenti,2 D. Wojciechowski.1

    1Division of Nephrology, Massachusetts General Hospital, Boston, MA; 2Division of Nephrology, UCSF, San Francisco, CA

    IntroductionBK viremia is a common complication following kidney transplantation. In vitro data suggest that inhibition of the mTOR–SP6-kinase pathway prevents expression of early viral genes…
  • 2017 American Transplant Congress

    Utility of “High-Dose” Ganciclovir in High Viral Load CMV Infection in Transplant Recipients.

    M. Alfares, R. Avery, N. Turki, K. Alfares, S. Mehta, R. Boger, A. Valsamakis.

    Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Pediatric Infectious Disease, Johns Hopkins, Baltimore, MD; Pathology, Johns Hopkins, Baltimore, MD

    Background: High-dose ganciclovir (GCV) is often used for treatment of high viral load CMV, but few data exist on virologic outcomes and risk of neutropenia.…
  • 2017 American Transplant Congress

    Impact of Timeliness of Assessment of Positive Cytomegalovirus Polymerase Chain Reaction Results in Abdominal Organ Transplant Recipients.

    K. Roach, H. Triemer, M. Hurtik, A. Mehta.

    Emory University Hospital, Atlanta, GA

    Purpose: The purpose of this study was to evaluate the timeliness of assessment of positive cytomegalovirus (CMV) polymerase chain reaction (PCR) results. This study served…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 14
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences